{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:20:30Z","timestamp":1792635630066,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012942","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000}}],"reference-count":214,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012942.pub2","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T19:16:56Z","timestamp":1738178216000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Antidepressants versus placebo for generalised anxiety disorder (GAD)"],"prefix":"10.1002","volume":"2025","author":[{"given":"Katarina","family":"Kopcalic","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics; Western University; London Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Arcaro","sequence":"additional","affiliation":[{"name":"School of Health Studies, Faculty of Health Sciences; Western University; London, Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pinto","sequence":"additional","affiliation":[{"name":"DMH ASI Napoli 3 sud; SITCC\/EABCT; Naples Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehzad","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics; Western University; London Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Barbui","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Biomedicine and Movement Sciences, Section of Psychiatry; University of Verona; Verona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Curatoli","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery; Fondazione IRCCS Istituto Neurologico \"Carlo Besta\"; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Martin","sequence":"additional","affiliation":[{"name":"Departments of Anesthesia & Perioperative Medicine, Epidemiology & Biostatistics; Schulich School of Medicine & Dentistry, University of Western Ontario; London Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Guaiana","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Department of Epidemiology and Biostatistics; Western University; St Thomas Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"10.1002\/14651858.CD012942.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1192\/bjp.179.1.15","article-title":"Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study","volume":"179","author":"Allgulander","year":"2001","journal-title":"British Journal of Psychiatry: Journal of Mental Science"},{"issue":"5","key":"10.1002\/14651858.CD012942.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.eurpsy.2004.05.010","article-title":"Social adjustment in generalised anxiety disorder: a long-term placebo-controlled study of venlafaxine extended release","volume":"19","author":"Boyer","year":"2004","journal-title":"European Psychiatry"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"S315","DOI":"10.1016\/S0924-977X(99)80423-4","article-title":"Dose-response efficacy of long-term treatment of venlafaxine extended-release in generalized anxiety disorder","volume":"-","author":"Hackett","year":"1999","journal-title":"European Neuropsychopharmacology"},{"issue":"9","key":"10.1002\/14651858.CD012942.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1176\/appi.ajp.161.9.1642","article-title":"Efficacy of sertraline in a 12-week trial for generalized anxiety disorder","volume":"161","author":"Allgulander","year":"2004","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0005|cit5","unstructured":"Austin C Allgulander C Dahl AA Ravindran AV Fayyad R Sertraline in GAD: HAM-A item and factor analyses 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco (CA)"},{"issue":"6","key":"10.1002\/14651858.CD012942.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1600-0447.2005.00529.x","article-title":"Sertraline in generalized anxiety disorder: efficacy in treating the psychic and somatic anxiety factors","volume":"111","author":"Dahl","year":"2005","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"1","key":"10.1002\/14651858.CD012942.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/hup.648","article-title":"Gender differences in clinical presentation and response to sertraline treatment of generalized anxiety disorder","volume":"20","author":"Steiner","year":"2005","journal-title":"Human Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD012942.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1136\/ebmh.10.2.45","article-title":"Escitalopram 10 mg daily is more effective than paroxetine and placebo for generalised anxiety disorder","volume":"10","author":"Baldwin","year":"2007","journal-title":"Evidence-Based Mental Health"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1192\/bjp.bp.105.012799","article-title":"Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study","volume":"189","author":"Baldwin","year":"2006","journal-title":"British Journal of Psychiatry: Journal of Mental Science"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0010|cit10","unstructured":"Chang C Bose A Bielski RJ Double-blind comparison of escitalopram and paroxetine in the long-term treatment of GAD 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York (NY)"},{"issue":"10","key":"10.1002\/14651858.CD012942.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/da.20355","article-title":"Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder","volume":"25","author":"Bose","year":"2008","journal-title":"Depression and Anxiety"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0012|cit12","unstructured":"A double-blind flexible dose comparison of escitalopram, venlafaxine XR and placebo in the treatment of generalized anxiety disorder. Scientific result summary; July 2003 Data on file"},{"issue":"6","key":"10.1002\/14651858.CD012942.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"874","DOI":"10.4088\/jcp.v67n0603","article-title":"Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study","volume":"67","author":"Brawman-Mintzer","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD012942.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"528","DOI":"10.4088\/JCP.v60n0805","article-title":"Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder","volume":"60","author":"Davidson","year":"1999","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0015|cit15","unstructured":"Derivan A Entsuah R Haskins T Rudolph R Aguiar L Double-blind, placebo-controlled study of once daily venlafaxine XR and buspirone in outpatients with generalized anxiety disorder (GAD) XXIst Collegium Internationale Neuro Psychopharmacologicum. 1998 July 12-16; Glasgow (UK)"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"S269","DOI":"10.1016\/S0924-977X(98)80500-2","article-title":"Double-blind, placebo comparator-controlled study of once daily venlafaxine XR (V-XR) and buspirone (Bsp) in outpatients with generalized anxiety disorder (GAD)","volume":"-","author":"Haskins","year":"1998","journal-title":"European Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD012942.pub2-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/da.10146","article-title":"Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study","volume":"19","author":"Davidson","year":"2004","journal-title":"Depression and Anxiety"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0018|cit18","unstructured":"Flexible-dose comparison of the safety and efficacy of escitalopram and placebo in the treatment of generalized anxiety disorder. Scientific result summary; 2002 Data on file"},{"issue":"1","key":"10.1002\/14651858.CD012942.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1755-5949.2008.00075.x","article-title":"Clinical evaluation of the Daily Assessment of Symptoms-Anxiety (DAS-A): a new instrument to assess the onset of symptomatic improvement in generalized anxiety disorder","volume":"15","author":"Feltner","year":"2009","journal-title":"CNS Neuroscience & Therapeutics"},{"issue":"12","key":"10.1002\/14651858.CD012942.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jpsychires.2007.09.005","article-title":"Development and evaluation of the Daily Assessment of Symptoms\u2013Anxiety (DAS-A) scale to evaluate onset of symptom relief in patients with generalized anxiety disorder","volume":"42","author":"Morlock","year":"2008","journal-title":"Journal of Psychiatric Research"},{"issue":"23","key":"10.1002\/14651858.CD012942.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1001\/jama.283.23.3082","article-title":"Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial","volume":"283","author":"Gelenberg","year":"2000","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0022|cit22","doi-asserted-by":"crossref","unstructured":"Haskins JT Rudolph R Aguiar L Entsuah R Salinas E Venlafaxine XR (V-XR) is an efficacious short and long-term treatment for generalized anxiety disorder (GAD) 11th European College of Neuropsychopharmacology Congress; 1998 October 31-November 4; Paris (France)","DOI":"10.1016\/S0924-977X(98)80488-4"},{"issue":"6","key":"10.1002\/14651858.CD012942.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/YIC.0000000000000096","article-title":"Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study","volume":"30","author":"Gommoll","year":"2015","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0024|cit24","unstructured":"Safety, efficacy and tolerability of vilazodone in patients with generalized anxiety disorder (VLZ-MD-06) clinicaltrials.gov\/study\/NCT01766401"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0025|cit25","unstructured":"Goodman WK Bose A Wang Q Flexible-dose comparison of the safety and efficacy of Lu 26-054 (escitalopram) and placebo in the treatment of generalized anxiety disorder. Forest Laboratories scientific result summary; July 2000 Data on file"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0026|cit26","unstructured":"Goodman WK Bose A Wang Q Flexible-dose comparison of the safety and efficacy of escitalopram and placebo in the treatment of generalized anxiety disorder. Forest Laboratories scientific result summary; March 2001 Data on file"},{"issue":"4","key":"10.1002\/14651858.CD012942.pub2-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/s0924-9338(03)00046-4","article-title":"A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalised anxiety disorder","volume":"184","author":"Hackett","year":"2003","journal-title":"European Psychiatry: Journal of the Association of European Psychiatrists"},{"issue":"3","key":"10.1002\/14651858.CD012942.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/YIC.0b013e32807fb1b2","article-title":"Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial","volume":"22","author":"Hartford","year":"2007","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0029|cit29","unstructured":"A comparison of duloxetine hydrochloride, marketed comparator, and placebo in the treatment of generalized anxiety disorder clinicaltrials.gov\/study\/NCT00122850"},{"issue":"2","key":"10.1002\/14651858.CD012942.pub2-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/yic.0b013e32831d7980","article-title":"Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial","volume":"24","author":"Kasper","year":"2009","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0031|cit31","unstructured":"Comparison of pregabalin versus venlafaxine XR and placebo in the treatment of generalized anxiety disorder clinicaltrials.gov\/study\/NCT00151450"},{"issue":"2","key":"10.1002\/14651858.CD012942.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"100","DOI":"10.4088\/pcc.v09n0203","article-title":"Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians","volume":"9","author":"Koponen","year":"2007","journal-title":"Primary Care Companion to the Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0033|cit33","unstructured":"Duloxetine compared with placebo in patients with generalized anxiety disorder clinicaltrials.gov\/study\/NCT00122824"},{"issue":"495","key":"10.1002\/14651858.CD012942.pub2-BIB0034|cit34","first-page":"772","article-title":"A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care","volume":"53","author":"Lenox-Smith","year":"2003","journal-title":"British Journal of General Practice: Journal of the Royal College of General Practitioners"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0035|cit35","unstructured":"Reynolds A Lenox-Smith AL Depressive symptoms in GAD and outcome of treatment with venlafaxine extended release 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans (LA)"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0036|cit36","unstructured":"Shaw A Reynolds A Lenox-Smith A Effects of venlafaxine extended release on psychic and somatic anxiety symptoms in GAD 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia (PA)"},{"issue":"1","key":"10.1002\/14651858.CD012942.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/ijcp.12328","article-title":"A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder","volume":"68","author":"Mahableshwarkar","year":"2014","journal-title":"International Journal of Clinical Practice"},{"issue":"1","key":"10.1002\/14651858.CD012942.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/hup.2371","article-title":"A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10\u2009mg in acute treatment of adults with generalized anxiety disorder","volume":"29","author":"Mahableshwarkar","year":"2014","journal-title":"Human Psychopharmacology"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0039|cit39","unstructured":"Study of efficacy and safety of vortioxetine (Lu AA21004) in treating generalized anxiety disorder clinicaltrials.gov\/study\/NCT00731120"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0040|cit40","unstructured":"An efficacy and safety study of vortioxetine (Lu AA21004) in treating generalized anxiety disorder clinicaltrials.gov\/study\/NCT00734071"},{"issue":"12","key":"10.1002\/14651858.CD012942.pub2-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.euroneuro.2012.07.011","article-title":"Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States","volume":"22","author":"Rothschild","year":"2012","journal-title":"European Neuropsychopharmacology: Journal of the European College of Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD012942.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/BF02245268","article-title":"Effects of alprazolam and imipramine on parasympathetic cardiac control in patients with generalized anxiety disorder","volume":"107","author":"McLeod","year":"1992","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD012942.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"771","DOI":"10.4088\/JCP.v67n0511","article-title":"Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine","volume":"67","author":"Montgomery","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0044|cit44","unstructured":"Study of generalized anxiety disorder clinicaltrials.gov\/study\/NCT00135525"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0045|cit45","unstructured":"Efficacy and safety of SR58611A in patients with a generalized anxiety disorder clinicaltrials.gov\/study\/NCT00252343"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0046|cit46","unstructured":"An eight-week study to evaluate the efficacy and safety of SR58611A in patients with generalized anxiety disorder clinicaltrials.gov\/study\/NCT00266747"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0047|cit47","unstructured":"An eight-week study to evaluate the efficacy and safety of saredutant in patients with generalized anxiety disorder clinicaltrials.gov\/study\/NCT00417118"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0048|cit48","unstructured":"A 10-week study evaluating the efficacy and safety of PD 0332334 in patients with generalized anxiety disorder clinicaltrials.gov\/study\/NCT00658008"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0049|cit49","unstructured":"Pharmacological treatment of generalized anxiety disorder in the elderly (Sert-GAD) clinicaltrials.gov\/study\/NCT00701675"},{"issue":"4","key":"10.1002\/14651858.CD012942.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/0269881108091588","article-title":"A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder","volume":"22","author":"Allgulander","year":"2008","journal-title":"Journal of Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD012942.pub2-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1017\/S0033291708003401","article-title":"Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial","volume":"39","author":"Nicolini","year":"2009","journal-title":"Psychological Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012942.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/tpj.2011.62","article-title":"Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder","volume":"13","author":"Perlis","year":"2013","journal-title":"Pharmacogenomics Journal"},{"issue":"6","key":"10.1002\/14651858.CD012942.pub2-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/00004850-200411000-00003","article-title":"Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study","volume":"19","author":"Nimatoudis","year":"2004","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0054|cit54","unstructured":"A double-blind, placebo controlled study to evaluate the efficacy and tolerability of paroxetine in patients with generalised anxiety disorder (GAD) www.gsk-studyregister.com\/en\/trial-details\/?id=29060\/637"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"S347","DOI":"10.1016\/S0924-977X(00)80446-0","article-title":"Paroxetine is effective in the treatment of generalized anxiety disorder: results from a randomized placebo-controlled flexible dose study","volume":"-","author":"McCafferty","year":"2000","journal-title":"European Neuropsychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD012942.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4088\/JCP.v62n0508","article-title":"Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial","volume":"62","author":"Pollack","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD012942.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1176\/appi.ajp.157.6.968","article-title":"Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder","volume":"157","author":"Rickels","year":"2000","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0058|cit58","unstructured":"A randomized, double-blind, placebo controlled, fixed dosage trial to evaluate the efficacy and tolerability of 20 and 40mg\/day paroxetine in patients with generalized anxiety disorder www.gsk-studyregister.com\/en\/trial-details\/?id=29060\/641"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0059|cit59","unstructured":"Bellew KM McCafferty JP Zaninelli R Paroxetine improves quality of life in patients with generalised anxiety disorder 10th International College of Neuropsychopharmacology Congress; 2000 July 9-13; Brussels (Belgium)"},{"issue":"4","key":"10.1002\/14651858.CD012942.pub2-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1176\/appi.ajp.160.4.749","article-title":"Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study","volume":"160","author":"Rickels","year":"2003","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD012942.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/da.20271","article-title":"Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial","volume":"25","author":"Rynn","year":"2008","journal-title":"Depression and Anxiety"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0062|cit62","unstructured":"Efficacy and safety of agomelatine (25-50 mg\/day) for 12 weeks in patients with generalized anxiety disorder: a randomised controlled trial www.isrctn.com\/ISRCTN75061806"},{"issue":"5","key":"10.1002\/14651858.CD012942.pub2-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/JCP.0b013e318184ff5b","article-title":"Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study","volume":"28","author":"Stein","year":"2008","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD012942.pub2-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/NMD.0b013e3181a77152","article-title":"The DSM-IV-based generalized anxiety disorder severity scale: preliminary validation using data from a trial of agomelatine versus placebo","volume":"197","author":"Stein","year":"2009","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0065|cit65","unstructured":"Efficacy and safety of agomelatine for 12 weeks in non-depressed out-patients with generalised anxiety disorder www.isrctn.com\/ISRCTN03554974"},{"issue":"4","key":"10.1002\/14651858.CD012942.pub2-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"362","DOI":"10.4088\/JCP.13m08433","article-title":"Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study","volume":"75","author":"Stein","year":"2014","journal-title":"Journal of Clinical Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD012942.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.euroneuro.2017.02.007","article-title":"Efficacy and safety of agomelatine (10 or 25 mg\/day) in non-depressed out-patients with generalized anxiety disorder: a 12-week, double-blind, placebo-controlled study","volume":"27","author":"Stein","year":"2017","journal-title":"European Neuropsychopharmacology: Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0068|cit68","unstructured":"Duloxetine for the treatment of generalized anxiety disorder clinicaltrials.gov\/study\/NCT00803361"},{"issue":"20","key":"10.1002\/14651858.CD012942.pub2-BIB0069|cit69","first-page":"3260","article-title":"Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China","volume":"124","author":"Wen-Yuan","year":"2011","journal-title":"Chinese Medical Journal"},{"issue":"9","key":"10.1002\/14651858.CD012942.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/gps.4088","article-title":"Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trial","volume":"29","author":"Alaka","year":"2014","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD012942.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1017\/S1461145705005973","article-title":"Prevention of relapse in generalized anxiety disorder by escitalopram treatment","volume":"9","author":"Allgulander","year":"2006","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD012942.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/0269881108091588","article-title":"A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder","volume":"22","author":"Allgulander","year":"2008","journal-title":"Journal of Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD012942.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/tpj.2011.62","article-title":"Pharmacogenetic investigation of response to duloxetine treatment in generalised anxiety disorder","volume":"13","author":"Perlis","year":"2013","journal-title":"Pharmacogenomics Journal"},{"issue":"12","key":"10.1002\/14651858.CD012942.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.euroneuro.2012.07.018","article-title":"On assessing potential efficacy for vortioxetine in generalized anxiety disorder","volume":"22","author":"Baldwin","year":"2012","journal-title":"European Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD012942.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/YIC.0b013e3283530ad7","article-title":"Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder","volume":"27","author":"Baldwin","year":"2012","journal-title":"International Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD012942.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/hup.1211","article-title":"Predictors of relapse in a study of duloxetine treatment for patients with generalized anxiety disorder","volume":"26","author":"Bodkin","year":"2011","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"issue":"8","key":"10.1002\/14651858.CD012942.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s11055-011-9498-2","article-title":"Efficacy of Adepress (paroxetine) in generalized anxiety disorder","volume":"41","author":"Chakhava","year":"2011","journal-title":"Neuroscience and Behavioral Physiology"},{"issue":"11","key":"10.1002\/14651858.CD012942.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.4088\/JCP.v66n1115","article-title":"Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder","volume":"66","author":"Davidson","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0079|cit79","doi-asserted-by":"crossref","unstructured":"Zheng H Pollack MH Bose A Efficacy and tolerability of escitalopram in the treatment of anxiety disorders XII World Congress of Psychiatry; 2002 August 24-29; Yokohama (Japan)","DOI":"10.1016\/S0924-977X(02)80541-7"},{"issue":"9","key":"10.1002\/14651858.CD012942.pub2-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.euroneuro.2008.05.002","article-title":"Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial","volume":"18","author":"Davidson","year":"2008","journal-title":"European Neuropsychopharmacology: Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0081|cit81","unstructured":"An 8-week, multicentre, randomised, double-blind, placebo-controlled, flexible dose study of pregabalin (300-600 mg\/day) and venlafaxine XR (75-225 mg\/day) for the acute treatment of DSM-IV generalized anxiety disorder in outpatients www.clinicaltrialsregister.eu\/ctr-search\/search?query=2004-001500-13"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0082|cit82","unstructured":"Duloxetine 60 to 120 mg once daily compared with placebo in the prevention of relapse in generalized anxiety disorder www.clinicaltrialsregister.eu\/ctr-search\/search?query=2004-002626-22"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0083|cit83","unstructured":"An 8 week, double blind, placebo controlled, phase 3 trial of pregabalin (150 600 mg\/day) in the adjunctive treatment of patients with generalized anxiety disorder (GAD) who have not optimally responded to existing therapies www.clinicaltrialsregister.eu\/ctr-search\/search?query=2006-006339-31"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0084|cit84","unstructured":"Efficacy and safety of agomelatine (25 mg\/day with potential blinded adjustment at 50 mg\/day) for 12 weeks in non-depressed out-patients with generalized anxiety disorder. A 12-week randomised, double-blind, placebo-controlled, with paroxetine (20 mg\/day with potential progressive blinded adjustment to 40 mg\/day) as validator, 3-arm parallel groups, international multicenter study www.clinicaltrialsregister.eu\/ctr-search\/search?query=2008-003421-17"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1016\/S0924-977X(02)80229-2","article-title":"The antidepressant duloxetine reduces anxiety symptom severity","volume":"20","author":"Goldstein","year":"2002","journal-title":"European Neuropsychopharmacology"},{"issue":"406","key":"10.1002\/14651858.CD012942.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.0065-1591.2000.acp29-05.x","article-title":"Venlafaxine XR in the treatment of anxiety","volume":"102","author":"Hackett","year":"2000","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"6","key":"10.1002\/14651858.CD012942.pub2-BIB0087|cit87","first-page":"455","article-title":"A clinical control study of venlafaxine and alprazolam in the treatment of general anxiety disorder","volume":"18","author":"Hong-Wei","year":"2006","journal-title":"Medical Journal of Chinese People's Health"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0088|cit88","unstructured":"Efficacy and safety of agomelatine (25-50 mg\/day) for 12 weeks in patients with generalized anxiety disorder: a randomised controlled trial www.isrctn.com\/ISRCTN75061806"},{"issue":"3","key":"10.1002\/14651858.CD012942.pub2-BIB0089|cit89","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003592.pub2","article-title":"Antidepressants for generalised anxiety disorder (GAD)","author":"Kapczinski","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD012942.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1017\/S1461145714000017","article-title":"Lavender oil preparation Silexan is effective in generalized anxiety disorder \u2013 a randomized, double-blind comparison to placebo and paroxetine","volume":"17","author":"Kasper","year":"2014","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD012942.pub2-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1586\/14737175.9.2.155","article-title":"Duloxetine in the treatment of generalized anxiety disorder","volume":"9","author":"Kornstein","year":"2009","journal-title":"Expert Review of Neurotherapeutics"},{"issue":"1","key":"10.1002\/14651858.CD012942.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1176\/appi.ajp.162.1.146","article-title":"Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial","volume":"162","author":"Lenze","year":"2005","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD012942.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1001\/jama.2008.977","article-title":"Escitalopram for older adults with generalized anxiety disorder \u2013 a randomized controlled trial","volume":"301","author":"Lenze","year":"2009","journal-title":"JAMA"},{"issue":"NA","key":"10.1002\/14651858.CD012942.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.2044-8260.1987.tb00718.x","article-title":"A controlled trial of treatments for generalized anxiety","volume":"26","author":"Lindsay","year":"1987","journal-title":"British Journal of Clinical Psychology"},{"issue":"6","key":"10.1002\/14651858.CD012942.pub2-BIB0095|cit95","first-page":"17","article-title":"Efficacy and tolerability of long-term venlafaxine XR therapy for GAD. Results of long-term, double-blind, placebo-controlled studies","volume":"106","author":"Lydiard","year":"1999","journal-title":"Postgraduate Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012942.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0022-3956(02)00005-5","article-title":"Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR","volume":"36","author":"Montgomery","year":"2002","journal-title":"Journal of Psychiatric Research"},{"issue":"11","key":"10.1002\/14651858.CD012942.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/archpsyc.1993.01820230054005","article-title":"Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam","volume":"50","author":"Rickels","year":"1993","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0924-977X(00)80077-2","article-title":"Older antidepressant drugs for generalized anxiety disorder: developing the concept","volume":"-","author":"Rickels","year":"2000","journal-title":"European Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD012942.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2165\/00044011-200019020-00009","article-title":"Treatment of generalised anxiety disorder with venlafaxine XR: a randomised, double-blind trial in comparison with buspirone and placebo","volume":"19","author":"Rolland","year":"2000","journal-title":"Clinical Drug Investigation"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0100|cit100","unstructured":"Sheehan DV The treatment of generalized anxiety disorder 9th Congress of the Association of European Psychiatrists; 1998 20-24 September; Copenhagen (Denmark)"},{"issue":"Suppl 22","key":"10.1002\/14651858.CD012942.pub2-BIB0101|cit101","first-page":"23","article-title":"Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder","volume":"60","author":"Sheehan","year":"1999","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0924-9338(11)71892-2","article-title":"Long-term treatment with agomelatine: prevention of relapse in patients with generalised anxiety disorder over 6 months","volume":"26","author":"Stein","year":"2011","journal-title":"European Psychiatry"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0103|cit103","first-page":"213","article-title":"Continued benefit of long-term paroxetine treatment for generalized anxiety disorder (GAD)","volume":"5","author":"Stocchi","year":"2002","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD012942.pub2-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"250","DOI":"10.4088\/jcp.v64n0305","article-title":"Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder","volume":"64","author":"Stocchi","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012942.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/01.jcp.0000104906.75206.8b","article-title":"A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder","volume":"24","author":"Westenberg","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD012942.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/00004714-199206000-00013","article-title":"Clomipramine treatment for generalized anxiety disorder","volume":"12","author":"Wingerson","year":"1992","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0107|cit107","first-page":"153","article-title":"Duloxetine in the treatment of generalized anxiety disorder","volume":"2","author":"Wright","year":"2009","journal-title":"International Journal of General Medicine"},{"issue":"10","key":"10.1002\/14651858.CD012942.pub2-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1185\/030079907X226087","article-title":"Health-related quality of life (HRQOL) among patients with generalised anxiety disorder: evaluation conducted alongside an escitalopram relapse prevention trial","volume":"23","author":"Allgulander","year":"2007","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0109|cit109","unstructured":"Jorgensen TR Despiegel N Francois C Escitalopram treatment improves quality of life of generalized anxiety disorder patients measured by SF-36 Quality of Life Research 2005 2146"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0110|cit110","first-page":"S213","article-title":"Improving the impairment and disability associated with generalised anxiety disorder with paroxetine treatment","volume":"-","author":"Baldwin","year":"2002","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD012942.pub2-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.euroneuro.2011.07.005","article-title":"Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?","volume":"22","author":"Baldwin","year":"2012","journal-title":"European Neuropsychopharmacology: Journal of the European College of Neuropsychopharmacology"},{"issue":"1-2","key":"10.1002\/14651858.CD012942.pub2-BIB0112|cit112","first-page":"97","article-title":"Doxepine vs placebo in the treatment of neurotic anxiety","volume":"23","author":"Busnello","year":"1974","journal-title":"Jornal Brasileiro de Psiquiatria"},{"issue":"1","key":"10.1002\/14651858.CD012942.pub2-BIB0113|cit113","first-page":"26","article-title":"Sheehan suicidality tracking scale (Sheehan-STS): preliminary results from a multicenter clinical trial in generalized anxiety disorder","volume":"6","author":"Coric","year":"2009","journal-title":"Psychiatry (Edgmont)"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0114|cit114","unstructured":"Derivan AT Entsuah R Haskins T Rudolph R Aguiar L Double-blind, placebo-controlled study of once-daily venlafaxine XR and buspirone in outpatients with generalized anxiety disorder (GAD) Annual meeting of the American College of Neuropsychopharmacology; 1997; Honolulu (HI)"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0115|cit115","doi-asserted-by":"crossref","unstructured":"Haskins JT Aguiar L Pallay A Rudolph R Double-blind, placebo-controlled study of once daily venlafaxine XR in outpatients with generalized anxiety disorder 11th European College of Neuropsychopharmacology Congress; 1998 October 31-November 4; Paris (France)","DOI":"10.1016\/S0924-9338(99)80380-0"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0116|cit116","first-page":"S533","article-title":"Comparison of symptom-free days in generalized anxiety disorder following treatment with pregabalin or venlafaxine-XR","volume":"1","author":"Hoffman","year":"2009","journal-title":"European Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD012942.pub2-BIB0117|cit117","first-page":"192","article-title":"A clinical study of venlafaxine in the treatment of generalized anxiety disorder","volume":"11","author":"Huang","year":"2003","journal-title":"Health Psychology Journal"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1016\/S0924-977X(02)80535-1","article-title":"A placebo-controlled study of pregabalin and venlafaxine treatment of GAD","volume":"12","author":"Kasper","year":"2002","journal-title":"European Neuropsychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD012942.pub2-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"888","DOI":"10.4088\/jcp.v62n1109","article-title":"Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder","volume":"62","author":"Meoni","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0120|cit120","unstructured":"Salinas E Hackett D A six-month evaluation of three dose levels of venlafaxine extended-released in nondepressed outpatients with GAD 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington (DC)"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0121|cit121","first-page":"S535","article-title":"Functional and quality of life impairment in generalized anxiety disorder: effect of short-term treatment with pregabalin and venlafaxine-XR","volume":"1","author":"Mychaskiw","year":"2009","journal-title":"European Psychiatry"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0122|cit122","first-page":"S534","article-title":"Insomnia and quality of life in generalized anxiety disorder: impact on clinical presentation and response to pregabalin and venlafaxine-XR","volume":"1","author":"Mychaskiw","year":"2009","journal-title":"European Psychiatry"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0123|cit123","unstructured":"An 8-week, double blind, placebo-controlled, multicenter study with paroxetine (20 mg q24) as positive control, evaluating the efficacy and safety of 2 fixed doses of SR58611A (175 mg q12 and 350 mg q12) in outpatients with generalized anxiety disorder www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2005-003180-23"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0124|cit124","unstructured":"An eight-week study to evaluate the efficacy and safety of SR58611A in patients with generalized anxiety disorder (ELECTRA) clinicaltrials.gov\/study\/NCT00332891"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0125|cit125","unstructured":"A North-American eight-week study to evaluate the efficacy and safety of saredutant in patients with generalized anxiety disorder clinicaltrials.gov\/study\/NCT00390650"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0126|cit126","unstructured":"Clinical study assessing a new scale to measure onset of action in generalized anxiety disorder clinicaltrials.gov\/study\/NCT00715039"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0127|cit127","unstructured":"Roberts J Ruggiero L Carpenter DJ Pitts CD Generalized anxiety disorder (GAD): treatment with paroxetine CR 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15; Boca Raton (FL)"},{"issue":"3","key":"10.1002\/14651858.CD012942.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0924-977X(93)90031-G","article-title":"The role of antidepressants in the treatment of generalized anxiety disorder (GAD)","volume":"3","author":"Schweizer","year":"1993","journal-title":"European Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD012942.pub2-BIB0129|cit129","first-page":"201","article-title":"Controlled comparison of bromazepam, amitriptyline, and placebo in anxiety-depressive neurosis","volume":"38","author":"Shammas","year":"1977","journal-title":"Diseases of the Nervous System"},{"issue":"2","key":"10.1002\/14651858.CD012942.pub2-BIB0130|cit130","first-page":"175","article-title":"Discriminating placebo and drug in generalized anxiety disorder (GAD) trials: single vs. multiple clinical raters","volume":"30","author":"Smith","year":"1994","journal-title":"Psychopharmacology Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD012942.pub2-BIB0131|cit131","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/10401230590932335","article-title":"Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes","volume":"17","author":"Stein","year":"2005","journal-title":"Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0132|cit132","doi-asserted-by":"crossref","unstructured":"Wurthmann C Klieser E Lehmann E Differential pharmacotherapy in chronic generalized anxiety disorder 11th European College of Neuropsychopharmacology Congress; 1998 October 31-November 4; Paris (France) 1998 S255 6","DOI":"10.1016\/S0924-977X(98)80461-6"},{"issue":"3","key":"10.1002\/14651858.CD012942.pub2-BIB0133|cit133","first-page":"167","article-title":"Paroxetine in treatment of generalized anxiety","volume":"20","author":"Xie","year":"2001","journal-title":"Chinese Journal of New Drugs and Clinical Remedies"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0134|cit134","unstructured":"A placebo-controlled, randomized, double-blind, multicenter study to evaluate the efficacy and safety of venlafaxine in Japanese outpatients with generalized anxiety disorder jrct.niph.go.jp\/en-latest-detail\/jRCT2031220156 https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-jRCT2031220156"},{"issue":"7299","key":"10.1002\/14651858.CD012942.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1136\/bmj.322.7299.1417","article-title":"Who should measure quality of life?","volume":"32","author":"Addington-Hall","year":"2001","journal-title":"BMJ"},{"issue":"9","key":"10.1002\/14651858.CD012942.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.4088\/JCP.09m05328gry","article-title":"Comorbidity of generalized anxiety disorder and substance use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"71","author":"Alegria","year":"2010","journal-title":"Journal of Clinical Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD012942.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1017\/S1461145705005973","article-title":"Prevention of relapse in generalized anxiety disorder by escitalopram treatment","volume":"9","author":"Allgulander","year":"2006","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD012942.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1600-0447.1991.tb03176.x","article-title":"The natural history of anxiety disorders","volume":"84","author":"Angst","year":"1991","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"1","key":"10.1002\/14651858.CD012942.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00406-008-0832-9","article-title":"The generalized anxiety spectrum: prevalence, onset, course and outcome","volume":"259","author":"Angst","year":"2009","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0140|cit140","volume-title":"Diagnostic and Statistical Manual of Mental Disorders \u2013 DSM-III","author":"American Psychiatric Association","year":"1980"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0141|cit141","volume-title":"Diagnostic and Statistical Manual of Mental Disorders \u2013 DSM-III-R","author":"American Psychiatric Association","year":"1987"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0142|cit142","volume-title":"Diagnostic and Statistical Manual of Mental Disorders \u2013 DSM-IV","author":"American Psychiatric Association","year":"1994"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0143|cit143","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2000"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0144|cit144","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"d1199","DOI":"10.1136\/bmj.d1199","article-title":"Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis","volume":"342","author":"Baldwin","year":"2011","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"7","key":"10.1002\/14651858.CD012942.pub2-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3109\/15622975.2011.624548","article-title":"An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder","volume":"13","author":"Baldwin","year":"2012","journal-title":"World Journal of Biological Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD012942.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/0269881114525674","article-title":"Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology","volume":"28","author":"Baldwin","year":"2014","journal-title":"Journal of Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD012942.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00002826-199310000-00002","article-title":"Neurobiological mechanisms involved in antidepressant therapies","volume":"16","author":"Briley","year":"1993","journal-title":"Clinical Neuropharmacology"},{"issue":"6","key":"10.1002\/14651858.CD012942.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1176\/appi.ajp.162.6.1179","article-title":"Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study","volume":"162","author":"Bruce","year":"2005","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD012942.pub2-BIB0150|cit150","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006115","article-title":"Azapirones for generalized anxiety disorder","author":"Chessick","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD012942.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis","volume":"159","author":"Cipriani","year":"2013","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012942.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"366","DOI":"10.5498\/wjp.v5.i4.366","article-title":"Treating comorbid anxiety and depression: psychosocial and pharmacological approaches","volume":"5","author":"Coplan","year":"2015","journal-title":"World Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012942.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.janxdis.2007.01.002","article-title":"A meta-analysis of CBT for pathological worry among clients with GAD","volume":"22","author":"Covin","year":"2008","journal-title":"Journal of Anxiety Disorders"},{"issue":"9","key":"10.1002\/14651858.CD012942.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.euroneuro.2008.05.002","article-title":"Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial","volume":"18","author":"Davidson","year":"2008","journal-title":"European Neuropsychopharmacology"},{"issue":"12","key":"10.1002\/14651858.CD012942.pub2-BIB0155|cit155","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008120.pub2","article-title":"Second-generation antipsychotics for anxiety disorders","author":"Depping","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD012942.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012942.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"e91455","DOI":"10.1371\/journal.pone.0091455","article-title":"Escitalopram or novel herbal mixture treatments during or following exposure to stress reduce anxiety-like behavior through corticosterone and BDNF modifications","volume":"9","author":"Doron","year":"2014","journal-title":"PLOS One"},{"issue":"1","key":"10.1002\/14651858.CD012942.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004850-200501000-00010","article-title":"Imputing response rates from means and standard deviations in meta-analyses","volume":"20","author":"Furukawa","year":"2005","journal-title":"International Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD012942.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0160|cit160","first-page":"pii: 1002","article-title":"Generalised anxiety disorder","volume":"2011","author":"Gale","year":"2011","journal-title":"BMJ Clinical Evidence"},{"issue":"11","key":"10.1002\/14651858.CD012942.pub2-BIB0161|cit161","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001846.pub3","article-title":"Benzodiazepines for generalised anxiety disorder (GAD)","author":"Gale","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD012942.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/14656566.2018.1472767","article-title":"Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review","volume":"19","author":"Gomez","year":"2018","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"1","key":"10.1002\/14651858.CD012942.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.janxdis.2011.08.010","article-title":"Interventions for generalized anxiety disorder in older adults: systematic review and meta-analysis","volume":"26","author":"Gon\u00e7alves","year":"2012","journal-title":"Journal of Anxiety Disorders"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0164|cit164","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2017"},{"issue":"3","key":"10.1002\/14651858.CD012942.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2174\/1871524911006030207","article-title":"The dual role of serotonin in defense and the mode of action of antidepressants on generalized anxiety and panic disorders","volume":"10","author":"Graeff","year":"2010","journal-title":"Central Nervous System Agents in Medicinal Chemistry"},{"issue":"12","key":"10.1002\/14651858.CD012942.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1017\/S0033291705006069","article-title":"Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"35","author":"Grant","year":"2005","journal-title":"Psychological Medicine"},{"issue":"12","key":"10.1002\/14651858.CD012942.pub2-BIB0167|cit167","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006815.pub2","article-title":"Hydroxyzine for generalised anxiety disorder","author":"Guaiana","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0168|cit168","first-page":"218","volume-title":"ECDEU Assessment Manual for Psychopharmacology \u2013 Revised (DHEW Publ No ADM 76-338)","author":"Guy","year":"1976"},{"issue":"12","key":"10.1002\/14651858.CD012942.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","article-title":"GRADE guidelines: 7. Rating the quality of evidence \u2013 inconsistency","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD012942.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence-imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0171|cit171","unstructured":"Hackett D White C Salinas E Relapse prevention in patients with generalised anxiety disorder (GAD) by treatment with venlafaxine ER 1st International Forum on Mood and Anxiety Disorders; 2000; Monte Carlo (Monaco)"},{"issue":"1","key":"10.1002\/14651858.CD012942.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"British Journal of Medical Psychology"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jpsychires.2019.08.009","article-title":"Comparative efficacy and acceptability of first-line drugs for the acute treatment of generalized anxiety disorder in adults: a network meta-analysis","volume":"118","author":"He","year":"2019","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0174|cit174","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from https:\/\/training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0175|cit175","unstructured":"Higgins JP Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from https:\/\/training.cochrane.org\/handbook\/archive\/v6.3"},{"issue":"4","key":"10.1002\/14651858.CD012942.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"621","DOI":"10.4088\/JCP.v69n0415","article-title":"Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials","volume":"69","author":"Hofmann","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012942.pub2-BIB0177|cit177","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001848.pub4","article-title":"Psychological therapies for generalised anxiety disorder","author":"Hunot","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012942.pub2-BIB0178|cit178","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/1471-244X-14-S1-S1","article-title":"Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders","volume":"14","author":"Katzman","year":"2014","journal-title":"BMC Psychiatry"},{"issue":"5-6 Suppl A","key":"10.1002\/14651858.CD012942.pub2-BIB0179|cit179","first-page":"4s","article-title":"Defining a clinically meaningful effect for the design and interpretation of randomized controlled trials","volume":"10","author":"Keefe","year":"2013","journal-title":"Innovations in Clinical Neuroscience"},{"issue":"2","key":"10.1002\/14651858.CD012942.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3109\/02813432.2014.920597","article-title":"Prevalence of anxiety disorders among Finnish primary care high utilizers and validation of Finnish translation of GAD-7 and GAD-2 screening tools","volume":"32","author":"Kujanp\u00e4\u00e4","year":"2014","journal-title":"Scandinavian Journal of Primary Health Care"},{"issue":"3","key":"10.1002\/14651858.CD012942.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/JCP.0b013e31821b2b3f","article-title":"Treating generalized anxiety disorder with second generation antipsychotics: a systematic review and meta-analysis","volume":"31","author":"LaLonde","year":"2011","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"12","key":"10.1002\/14651858.CD012942.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1007\/s00127-005-0978-y","article-title":"Generalised anxiety disorder in Singapore: prevalence, co-morbidity and risk factors in a multi-ethnic population","volume":"40","author":"Lim","year":"2005","journal-title":"Social Psychiatry and Psychiatric Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD012942.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2011.1360","article-title":"Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis","volume":"306","author":"Maher","year":"2011","journal-title":"JAMA"},{"issue":"10","key":"10.1002\/14651858.CD012942.pub2-BIB0184|cit184","first-page":"980","article-title":"Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication-Adolescent Supplement (NCS-A)","volume":"49","author":"Merikangas","year":"2010","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012942.pub2-BIB0185|cit185","first-page":"141","article-title":"A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder","volume":"25","author":"Mitte","year":"2005","journal-title":"Journal of Clinical Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD012942.pub2-BIB0186|cit186","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004515.pub2","article-title":"Valerian for anxiety disorders","author":"Miyasaka","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD012942.pub2-BIB0187|cit187","first-page":"1","article-title":"Dealing with the positive publication bias: why you should really publish your negative results","volume":"27","author":"Mlinari\u0107","year":"2017","journal-title":"Biochemia Medica (Zagreb)"},{"issue":"1","key":"10.1002\/14651858.CD012942.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0193-953X(05)70205-7","article-title":"Comorbidity in generalized anxiety disorder","volume":"24","year":"2001","journal-title":"Psychiatric Clinics of North America"},{"issue":"4","key":"10.1002\/14651858.CD012942.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"413","DOI":"10.31887\/DCNS.2011.13.4\/cotte","article-title":"Cognitive behavioral therapy in anxiety disorders: current state of the evidence","volume":"13","author":"Otte","year":"2011","journal-title":"Dialogues in Clinical Neuroscience"},{"issue":"12","key":"10.1002\/14651858.CD012942.pub2-BIB0190|cit190","first-page":"50","article-title":"Time to response in generalized anxiety disorder in a naturalistic setting: combination therapy with alprazolam orally disintegrating tablets and serotonin reuptake inhibitors compared to serotonin reuptake inhibitors alone","volume":"3","author":"Rapaport","year":"2006","journal-title":"Psychiatry (Edgmont)"},{"issue":"2","key":"10.1002\/14651858.CD012942.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jad.2011.11.014","article-title":"Humanistic and economic burden of generalized anxiety disorder in North America and Europe","volume":"140","author":"Revicki","year":"2012","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0192|cit192","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"issue":"16","key":"10.1002\/14651858.CD012942.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1517\/14656566.2011.618496","article-title":"Pharmacological treatment of generalized anxiety disorder","volume":"12","author":"Reinhold","year":"2011","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"12","key":"10.1002\/14651858.CD012942.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1001\/archgenpsychiatry.2010.170","article-title":"Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release","volume":"67","author":"Rickels","year":"2010","journal-title":"Archives of General Psychiatry"},{"issue":"1-3","key":"10.1002\/14651858.CD012942.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jad.2010.05.009","article-title":"Generalized anxiety disorder, with or without co-morbid major depressive disorder, in primary care: prevalence of painful somatic symptoms, functioning and health status","volume":"127","author":"Romera","year":"2010","journal-title":"Journal of Affective Disorders"},{"issue":"2","key":"10.1002\/14651858.CD012942.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/YIC.0b013e328341bb4a","article-title":"Efficacy and safety of treatments for refractory generalized anxiety disorder: a systematic review","volume":"26","author":"Samuel","year":"2011","journal-title":"International Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD012942.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3109\/00048674.2010.522554","article-title":"Kava: a comprehensive review of efficacy, safety, and psychopharmacology","volume":"45","author":"Sarris","year":"2011","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0198|cit198","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9781615370047","volume-title":"Manual of Clinical Psychopharmacology","author":"Schatzberg","year":"2015"},{"issue":"1","key":"10.1002\/14651858.CD012942.pub2-BIB0199|cit199","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/14651858.CD003592","article-title":"The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta-analysis","volume":"27","author":"Schmitt","year":"2005","journal-title":"Revista Brasileira de Psiquatria"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0200|cit200","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html"},{"issue":"2","key":"10.1002\/14651858.CD012942.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00127-009-0056-y","article-title":"Prevalence of mental disorders in primary care: results from the diagnosis and treatment of mental disorders in primary care study (DASMAP)","volume":"45","author":"Serrano-Blanco","year":"2010","journal-title":"Social Psychiatry and Psychiatric Epidemiology"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1146\/annurev-psych-010418-102803","article-title":"How to do a systematic review: a best practice guide for conducting and reporting narrative reviews, meta-analyses, and meta-syntheses","volume":"70","author":"Siddaway","year":"2019","journal-title":"Annual Review of Psychology"},{"issue":"2","key":"10.1002\/14651858.CD012942.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4088\/JCP.s.7002.02","article-title":"Generalized anxiety disorder and psychiatric comorbidities such as depression, bipolar disorder, and substance abuse","volume":"70","author":"Simon","year":"2009","journal-title":"Journal of Clinical Psychiatry"},{"issue":"10173","key":"10.1002\/14651858.CD012942.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0140-6736(18)31793-8","article-title":"Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis","volume":"393","author":"Slee","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD012942.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4088\/JCP.v64n0305","article-title":"Efficacy and tolerability of paroxetine for the long term treatment of generalized anxiety disorder","volume":"64","author":"Stocchi","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012942.pub2-BIB0206|cit206","doi-asserted-by":"publisher","first-page":"pii: pyv081","DOI":"10.1093\/ijnp\/pyv081","article-title":"Suicide behavior before and after the start with antidepressants: a high persistent risk in the first month of treatment among the young","volume":"19","author":"Termorshuizen","year":"2015","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD012942.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40263-013-0067-9","article-title":"Publication bias, with a focus on psychiatry: causes and solutions","volume":"27","author":"Turner","year":"2013","journal-title":"CNS Drugs"},{"issue":"9553","key":"10.1002\/14651858.CD012942.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/S0140-6736(06)69865-6","article-title":"Generalised anxiety disorder","volume":"368","author":"Tyrer","year":"2006","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0209|cit209","volume-title":"The Ninth Revision of the International Classification of Diseases and Related Health Problems (ICD-9)","author":"World Health Organization","year":"1978"},{"key":"10.1002\/14651858.CD012942.pub2-BIB0210|cit210","volume-title":"The Tenth Revision of the International Classification of Diseases and Related Health Problems (ICD-10)","author":"World Health Organization","year":"1992"},{"issue":"4","key":"10.1002\/14651858.CD012942.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/da.10065","article-title":"Generalized anxiety disorder: prevalence, burden, and cost to society","volume":"16","author":"Wittchen","year":"2002","journal-title":"Depression and Anxiety"},{"issue":"2","key":"10.1002\/14651858.CD012942.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/(SICI)1522-7154(1996)2:2<71::AID-ANXI2>3.0.CO;2-G","article-title":"Comparison of RDC, DSM-III, DSM-III-R diagnostic criteria for generalized anxiety disorder","volume":"2","author":"Wolk","year":"1996","journal-title":"Anxiety"},{"issue":"3","key":"10.1002\/14651858.CD012942.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/YIC.0b013e3283427cd7","article-title":"Assessment of quality of life enjoyment and satisfaction questionnaire-short form responder thresholds in generalized anxiety disorder and bipolar disorder studies","volume":"26","author":"Wyrwich","year":"2011","journal-title":"International Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD012942.pub2-BIB0214|cit214","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012942","article-title":"Antidepressants versus placebo for generalised anxiety disorder (GAD)","author":"Guaiana","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:06:13Z","timestamp":1784505973000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012942.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":214,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012942.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]}}}